The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years?

Journal of Urology

Volumn 172, Issue 4 I, 2004, Pages 1297-1301

  Stamey, Thomas A ^a   Caldwell, Mitchell ^a   McNeal, John E ^a   Nolley, Rosalie ^a   Hemenez, Marci ^a   Downs, Joshua ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biological markers; Prostate specific antigen; Prostatic hyperplasia; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MULTIPLE REGRESSION; ORGAN SIZE; PALPATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; UNITED STATES;

EID: 4544254807     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000139993.51181.5d     Document Type: Article

References (20)

1. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med, 317: 909, 1987
2. Stamey, T. A., Kabalin, J. N., McNeal, J. E., Johnstone, I. M., Freiha, F., Redwine, E. A. et al: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol, 141: 1076, 1989
3. Stamey, T. A.: Preoperative serum prostate-specific antigen (PSA) below 10 microg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. Clin Chem, 47: 631, 2001
4. Stamey, T. A., Johnstone, I. M., McNeal, J. E., Lu, A. Y. and Yemoto, C. M.: Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with postradical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol, 167: 103, 2002
5. Stamey, T. A., McNeal, J. E., Yemoto, C. M., Sigal, B. M. and Johnstone, I. M.: Biological determinants of cancer progression in men with prostate cancer. JAMA, 281: 1395, 1999
6. Noguchi, M., Stamey, T. A., McNeal, J. E. and Yemoto, C. M.: Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. J Urol, 164: 1596, 2000
7. Orozco, R., Kunnel, B., O'Dowd, G. J. and Stamey, T. A.: Positive prostate biopsy rate consistently increases with age at the same prostate-specific antigen level in patients with normal digital rectal examination. Urology, 51: 531, 1998
8. Veltri, R. W., Miller, M. C., O'Dowd, G. J. and Partin, A. W.: Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. Urology, suppl., 60: 47, 2002
9. Noldus, J. and Stamey, T. A.: Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volume as measured by correlation coefficients. J Urol, 155: 232, 1996
10. McNeal, J. E. and Haillot, O.: Patterns of spread of adenocarcinoma in the prostate as related to cancer volume. Prostate, 49: 48, 2001
11. Noguchi, M., Stamey, T. A., McNeal, J. E. Mc. and Yemoto, C. E. M.: An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol, 163: 1751, 2000
12. Hodge, K. K., McNeal, J. E., Terris, M. K. and Stamey, T. A.: Random systematic versus directed ultrasound-guided transrectal core-biopsies of the prostate. J Urol, 142: 71, 1989
13. Presti, J. C., Jr., O'Dowd, G. J., Miller, M. C., Mattu, R. and Veltri, R. W.: Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol, 169: 125, 2003
14. Stewart, C. S., Leibovich, B. C., Weaver, A. L. and Lieber, M. M.: Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol, 166: 86, 2001
15. Ries, L. A. G., Eisner, M. P., Kosary, C. L., Hankey, B. F., Miller, B. A., Clegg, L. et al: SEER Cancer Statistics Review, 1975-2000, Bethesda: National Cancer Institute, http://seer.cancer.gov/csr/1975_2000 2003
16. Sakr, W. A., Grignon, D. J., Haas, G. P., Heilbrun, L. K., Pontes, J. E. and Crissman, J. D.: Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol, 30: 138, 1996
17. Rich, A. R.: On the frequency of occurrence of occult carcinoma of the prostate. J Urol, 33: 215, 1935
18. McNaughton Collins, M., Ransohoff, D. F. and Barry, M. J.: Early detection of prostate cancer. Serendipity strikes again. JAMA, 278: 1516, 1997
19. Punglia, R. S., D'Amico, A. V., Catalona, W. J., Roehl, K. A. and Kuntz, K. M.: Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med, 349: 335, 2003
20. Roehrborn, C. G., McConnell, J., Bonilla, J., Rosenblatt, S., Hudson, P. B., Malek, G. H. et al: Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol, 163: 13, 2000